Inventor Declaration Excluded by PTAB Because Examination in Foreign Proceeding No Substitute for Cross-Examination by IPR Counsel

Apr 11, 2022

Reading Time : 3 min

The petitioner challenged two patents related to streaming media content. The patents each name Jin Young Lee and Truong Cong Thang as the sole inventors. After the PTAB instituted review on both patents, the patent owner filed motions to amend. In opposition, the petitioner asserted a new prior art reference under Pre-AIA § 102(a). The asserted reference named six authors, two of whom were Mr. Lee and Mr. Thang.

In reply, the patent owner submitted a declaration of Mr. Lee, which supported the argument that the asserted reference was “authored by the same inventive entity” as the challenged patents and thus was not prior art under § 102(a). The patent owner was unable to produce Mr. Lee for cross-examination in the IPR, however. Apparently, Mr. Lee “understood that . . . he would be questioned about [his declaration only] during his upcoming examination in Korea” as part of the parallel district court proceedings—an examination in which only a Korean judge and the petitioner’s separate Korean counsel could ask questions. In place of producing Mr. Lee for cross-examination in the IPR, the patent owner offered to allow the petitioner to submit transcripts from the Korean examination. The petitioner rejected the offer and moved to exclude Mr. Lee’s declaration.

In its motions to exclude, the petitioner argued that failing to make Mr. Lee available for cross-examination violated the PTAB’s discovery rules, that Mr. Lee’s declaration was inadmissible hearsay, and that submitting a transcript of the Korean examination—in place of cross-examination by its IPR counsel—would prejudice the petitioner. In response, the patent owner argued that the Korean examination qualified as a “cross-examination” in the IPR proceedings and, alternatively, that a hearsay exception applied under FRE 804(b)(1) because the petitioner’s Korean counsel had “an opportunity and similar motive to develop” Mr. Lee’s declaration testimony in Korea.

The PTAB agreed with the petitioner and excluded Mr. Lee’s declaration. As the PTAB explained, “the rules governing routine discovery” allow the PTAB “to consider Mr. Lee’s testimony in his Declaration” only if the patent owner “make[s] Mr. Lee available for cross-examination by Petitioner”—which it failed to do. See 37 C.F.R. §§ 42.51–42.53. The Korean examination did not satisfy the PTAB’s rules because depositions “outside the United States may only be taken upon agreement of the parties or as the Board specifically directs”—neither of which occurred. Id. § 42.53(b)(3). The patent owner also failed to “initiate a conference with the Board at least five business days before” the examination, as required for depositions involving an interpreter. Id. § 42.53(e). Finally, the Board explained that Mr. Lee’s “understanding” that he would only be examined in Korea was not “an extraordinary circumstance” that could justify his unavailability.

The PTAB also excluded Mr. Lee’s declaration as inadmissible hearsay under FRE 801 and 802 because it included out-of-court statements offered for their truth. An exception under FRE 804(b)(1) did not apply because the petitioner did not have “an opportunity . . . to develop” Mr. Lee’s testimony by cross-examination. The PTAB rejected the patent owner’s argument that the Korean examination was an “opportunity” for cross-examination because the petitioner’s IPR counsel could not participate in the examination. Additionally, no evidence showed that the examination followed the procedures for foreign-language depositions set forth in Ariosa Diagnostics v. ISIS Innovation Ltd., IPR2012-00022, Paper 55 (PTAB Aug. 7, 2013) (informative).

Finally, the PTAB explained that excluding the declaration was an appropriate remedy because allowing it to remain in the record would prejudice the petitioner. Namely, “[t]he admissibility [of] the Lee Declaration [wa]s no tangential matter––it [went] to the heart of whether [a key reference] constitute[d] prior art.” Indeed, it was “the only (remaining) piece of evidence in the record that addresse[d] the inventive entity” of the reference. Thus, denying the motion to exclude would have “significantly impact[ed] Petitioner’s ability to address a dispositive issue.”

Practice Tip: Practitioners should proceed with caution when relying on declarants in PTAB proceedings, particularly when the declarants reside in foreign countries. Practitioners should ensure that their declarants are willing and able to sit for a deposition in the IPR proceedings—even if they have been or will be deposed on related subject matter in related proceedings. Moreover, for depositions in foreign countries, practitioners should ensure that they confer with opposing counsel, or get authorization from the PTAB, in a timely manner pursuant to 37 C.F.R. § 42.53(b)(3). Finally, for foreign-language depositions, practitioners must be sure to follow the rules and guidelines set forth in 37 C.F.R. § 42.53(e) and Ariosa Diagnostics.

Vudu, Inc. v. IdeaHub, Inc., IPR2020-01688, Paper 47, IPR2020-01689, Paper 48 (PTAB Mar. 16, 2022).

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.